Gut 2004, 53:925–930 PubMedCentralPubMedCrossRef 6 Zhang X, Wats

Gut 2004, 53:925–930.PubMedCentralPubMedCrossRef 6. Zhang X, Watson DI, Jamieson GG, Bessell JR, Devitt PG: Neoadjuvant chemoradiotherapy for esophageal carcinoma. Dis Esophagus 2005, 18:104–108.PubMedCrossRef 7. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J, Australasian Gastro-Intestinal Trials

Group: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in RSL3 molecular weight oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007, 8:226–234.PubMedCrossRef 8. Reynolds JV, Muldoon C, Hollywood D, Ravi N, Rowley S, O’Byrne K, Kennedy J, Murphy TJ: Long-term outcomes following neoadjuvant chemoradiotherapy. Ann Surg 2007, 245:707–716.PubMedCentralPubMedCrossRef 9. Sjoquist KM, Burmeister

BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour Selleck Barasertib A, Gebski V, Australasian Gastro-Intestinal Trials Group: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011, 12:681–692.PubMedCrossRef 10. Hummel R, Watson DI, Smith C, Kist J, Michael MZ, Haier J, Hussey DJ: Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg 2011, 15:429–438.PubMedCrossRef 11. Willett CG, Czito BG: Chemoradiotherapy in gastrointestinal malignancies. Clin Oncol 2009, 21:543–556.CrossRef 12. Pantling AZ, Gossage JA, Mamidanna R, Newman G, Robinson A,

Manifold DK, Hale PC: Outcomes from chemoradiotherapy for patients with esophageal cancer. Dis Esophagus 2011, 24:172–176.PubMedCrossRef 13. Spugnini EP, Citro G, Fais S: Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. J Exp Clin Cancer Res 2010, 8:44.CrossRef 14. De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M, Marino ML, Federici C, Perdicchio M, Matarrese P, Lugini L, Nilsson A, Fais S: crotamiton Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res 2007, 67:5408–5417.PubMedCrossRef 15. Raghunand N, Mahoney BP, Gillies RJ: Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on selleck kinase inhibitor pharmacokinetics of weakly basic chemotherapeutic agents. Biochem Pharmacol 2003, 66:1219–1229.PubMedCrossRef 16. You H, Jin J, Shu H, Yu B, De Milito A, Lozupone F, Deng Y, Tang N, Yao G, Fais S, Gu J, Qin W: Small interfering RNA targeting the subunit ATP6L of proton pump V-ATPase overcomes chemoresistance of breast cancer cells. Cancer Lett 2009, 280:110–119.PubMedCrossRef 17.

Comments are closed.